Impact of Preanalytical Sample Preparation on the Recovery Rate of Cryopreserved Allogeneic Hematopoietic Stem Cells
Authors:
Open Access
- 19 January 2026
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 116 (5) , 604-614
Abstract
Introduction: Cryopreservation of peripheral‐blood‐derived hematopoietic stem and progenitor cells (PBSCs) has been used for decades, primarily for autologous transplantation. Now, in the era of new cellular therapies, the cryopreservation of allogeneic PBSCs may also become relevant. While the defining quality‐control parameters are assessed before cryopreservation, in thawed cryopreserved samples the viability of total nucleated cells is often the only parameter analyzed. We therefore evaluated the recovery rates of total and viable CD45 + and CD34 + cells after cryopreservation. Methods: Thirty‐nine samples of allogeneic PBSC products were analyzed before and after cryopreservation. Post‐thaw viability was assessed using trypan blue exclusion. To investigate the influence of different preanalytical preparation methods, PBSCs were resuspended in phosphate‐buffered saline (PBS) or human serum albumin (HSA), and the cells suspended in HSA were tested without incubation or following incubation at 37°C for 1 h or 2 h. The number and viability of CD45 + and CD34 + cells were evaluated by flow cytometry and compared with pre‐thaw values. Results: After cryopreservation, we observed significant decreases in both total and viable CD45 + cell numbers. In contrast, the difference in total CD34 + cell numbers was rather small, whereas the median recovery rate of viable CD34 + cells after resuspension in PBS was 70.1%. Relevant differences between the preanalytical treatment groups could not be observed. The viability values as determined by trypan blue viability staining and flow cytometry were not correlated. Conclusion: Determination of the CD34 + cell recovery rate after thawing is feasible and may be used as an additional parameter for quality control for cryopreserved allogeneic PBSCs. However, the results of currently used viability assays vary considerably, making comparisons between different cell processing units and cryopreservation protocols difficult. Therefore, available protocols should be carefully evaluated based on “good‐manufacturing‐practice” (GMP) regulations before implementation.Keywords
This publication has 40 references indexed in Scilit:
- Assessment and comparison of viability assays for cellular productsCytotherapy, 2023
- Cryopreservation of Growth Factor-Mobilized Peripheral Blood Stem Cells Does Not Compromise Major Outcomes after Allogeneic Hematopoietic Cell Transplantation: A Single-Center ExperienceTransplantation and Cellular Therapy, 2023
- Cryopreserved hematopoietic stem/progenitor cells stability program-development, current status and recommendations: A brief report from the AABB-ISCT joint working group cellular therapy product stability project teamCytotherapy, 2022
- Collection, Cryostorage, Transplantation, and Disposal of Hematopoietic Stem Cell ProductsTransplantation and Cellular Therapy, 2019
- Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow TransplantationCytotherapy, 2018
- Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after TransplantationTransplantation and Cellular Therapy, 2017
- Current practices and prospects for standardization of the hematopoietic colony-forming unit assay: a report by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) CollaborativeCytotherapy, 2013
- ISHAGE protocol: Are we doing it correctly?Cytometry Part B: Clinical Cytometry, 2011
- Cryopreservation of hematopoietic stem cellsAmerican Journal of Hematology, 2007
- Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelinesCytometry, 1998